Loading stock data…
BBIO
$68.56-2.55 (-3.59%)
Market ClosedLast close May 1
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BridgeBio Pharma, Inc. in the Healthcare sector is trading at $68.56. The stock is currently 19% below its 52-week high of $84.94, remaining 6.5% above its 200-day moving average. Technical signals show oversold RSI of 24 and bearish MACD signal, explaining why BBIO maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 24) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$68.56
Potential Upside
5%
Whystock Fair Value$71.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Mean target$101.06+47.4%
Range$80.00 – $157.00
Fundamentals
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
37.21%
Volume
Today's trading volume
1.72M
Recent News
Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%
Alnylam stock popped Thursday on a solid first-quarter beat for its Pfizer-rivaling heart disease drug, Amvuttra.
Is Attruby’s Accelerating Launch and Star-Studded Awareness Campaign Altering The Investment Case For BridgeBio Pharma (BBIO)?
BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical efficacy data, particularly in treatment‑naive patients. The company has also rolled out a national ATTR-CM health education campaign featuring Morgan Freeman and Howard “H” White, a move that both raises disease awareness and underscores BridgeBio’s ambition to build a meaningful commercial foothold...
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio (BBIO) Q2 2025 Earnings Transcript
Chinmay Shukla: Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Second Quarter 2025 Earnings Call. With me today are Neil Kumar, our CEO; Matt Outten, our Chief Commercial Officer; and Tom Trimarchi, our President and Chief Financial Officer. For the Q&A session, we'll also be joined by Ananth Sridhar, Justin To and Christine Siu who lead our Phase III programs.
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.